Effect of Exogenous Fibroblast Growth Factor-21 on Inflammation in a High-fat Diet and Cholesterol Mice Model

Zhihao DONG¹ Yuanyuan CHEN¹ Wei YANG¹ Ruirui Ll¹ Sansi GAO¹ Ping HE¹ Baoyin HUANG¹ Runqi LIU¹ Han GUO¹ Renxu CHANG¹ Cheng XIA¹ Chuang XU¹

¹ College of Animal Science and Veterinary Medicine, Heilongjiang Bayi Agricultural University, Daqing, Heilongjiang 163319, CHINA

Article Code: KVFD-2017-18282 Received: 03.07.2017 Accepted: 17.10.2017 Published Online: 20.10.2014

Citation of This Article

Dong Z, Chen Y, Yang W, Li R, Gao S, He P, Huang B, Liu R, Guo H, Chang R, Xia C, Xu C: Effect of exogenous fibroblast growth factor-21 on inflammation in a high-fat diet and cholesterol mice model. *Kafkas Univ Vet Fak Derg*, 24 (1): 61-68, 2018. DOI: 10.9775/kvfd.2017.18282

Abstract

Fibroblast Growth Factor 21 (FGF21) is a novel metabolic regulator involved in lipid utilization, and it can involve in the regulation of lipid metabolism. To determine the physiological function of FGF21 in relation to a high-fat diet (HFD) and high cholesterol, the effect of FGF21 on immune response indicators and hematological parameters was investigated. In the experiment, a total of 24 female mice were selected, 12 of which were fed with HFDs (group 1) and the other were fed with normal diet (group 2). After 30 days, the mice of two groups were respectively divided into two groups on average: 1. HFDs mice were used as model group; 2 normal diet mice were used as control group; 3. HFDs mice injection were used as model + FGF21 group; 4. normal diet injection were used as control + FGF21 group. Mice were sacrificed at 3-day intervals and the livers were isolated and analyzed. Blood was collected and analyzed for CD3 and CD19 by flow cytometry and IL-4, IL-6 and TNF- α by ELISA. Serum TG, TC, NEFA, LDL-c, and HDL-c levels were measured by automatic biochemical analyzer. Although CD3 and CD19 varied, the difference was not significant, and the levels of IL-4, IL-6, TNF- α , TC, TG LDL-c, and NEFA in the model exogenous injection FGF21 group were lower than in the model group (P<0.05). The present results indicate that exogenous FGF21 regulates IL-4, IL-6 and TNF- α and protects the liver from inflammation damage induced by high dietary fat and cholesterol.

Keywords: Exogenous FGF21, High-fat diets, Cholesterol, Immunological factor

Yüksek Yağlı Diyet ve Kolesterolle Beslenen Farelerde Eksojen Fibroblast Büyüme Faktörü-21'in Yangı Üzerine Etkisi

Özet

Fibroblast Büyüme Faktörü 21 (FGF21) yağların kullanımında görev alan metabolik bir düzenleyicidir ve yağ metabolizmasında rol oynar. Yüksek yağlı ve kolesterollü diyet ile FGF21'in fizyolojik fonksiyonu arasındaki ilişkiyi araştırmak amacıyla FGF21'in bağışıklık cevap indikatörleri ve kan parametreleri üzerine etkisi incelendi. Çalışmada toplam 24 dişi fare kullanıldı ve bunların 12'si yüksek yağlı diyet (Grup 1) diğer 12'si ise normal diyet (Grup 2) ile beslendi. Otuz gün sonunda iki gruptaki fareler tekrar ikişer gruba bölündü; 1: Yüksek yağlı diyet ile beslenen fareler "model grup" olarak kullanıldı, 2: Normal diyet fareler "kontrol grubu" olarak kullanıldı; 3: Yüksek yağlı diyet ile beslenen ve FGF21 enjekte edilen fareler "model + FGF21 grubu" olarak kullanıldı; 4: normal ile beslenen ve FGF21 enjekte edilen fareler "kontrol + FGF21 grubu" olarak kullanıldı. Fareler 3 gün aralıkla öldürüldü ve karaciğer dokuları incelendi. Kan toplanarak CD3 ve CD19 akışkan sitometresi ve IL-4, IL-6 ve TNF-α ise ELİSA ile analiz edildi. Serum TG, TC, NEFA, LDL-c ve HDL-c seviyeleri otomatik biyokimyasal analizleyici ile ölçüldü. CD3 ve CD19 değişmekle birlikte değişim istatistiki bakımdan anlamlı bulunmadı ve model eksojen enjeksiyon FGF21 grubunda IL-4, IL-6, TNF-α, TC, TG LDL-c ve NEFA seviyeleri model grubundan daha düşük olarak tespit edildi (P<0.05). Mevcut çalışmanın sonuçları eksojen FGF21'in IL-4, IL-6, ve TNF-α ekspresyonlarını düzenlediğini ve yüksek diyetsel yağ ve kolesterol ile oluşturulan karaciğer yangısal hasarına karşı organı koruduğunu göstermektedir.

Anahtar sözcükler: Eksojen FGF21, Yüksek yağlı diyet, Kolesterol, İmmunolojik faktör

INTRODUCTION

High-fat diets (HFDs) can increase the risk of many metabolic

diseases, such as insulin resistance, hypertension, hyperlipemia, and liver disease^[1]. HFDs is also closely related to metabolic inflammation, especially in the liver^[2,3]. Liver

iletişim (Correspondence)

- 🕾 +86 459 6819121 (C. Xu); +86 18249636785 (Y. Chen)
- xuchuang7175@163.com (C. Xu); 897533029@qq.com (Y. Chen)

is an important organ that regulates the energy homeostasis of the body ^[4]. Liver steatosis is not only confined to liver damage, but also closely associated with disorders of glucolipid metabolism ^[5].

A HFDs causes resistance of skeletal muscle glucose transport to insulin and contractions. HFDs-fed mice show glucose intolerance and decreased insulin sensitivity, accompanying by impaired insulin signaling. A HFDs can affect immunity functions and energy metabolism in the body. HFDs cause chronic inflammation, potentially damaging the liver's innate immune system. The abnormalities of the hepatic innate immune system (macrophages, neutrophils, and natural killer T cells) lead to the increased production of inflammatory cytokines, which contribute to the chronic inflammatory state of liver injury ^[6]. Inflammatory stress is closely related to metabolic disease and insulin resistance, implying that chronic inflammation accelerates the deterioration of B cell function. There are a number of ways to regulate the energy disorders caused by HFDs, such as reducing FFA production, inhibiting TNF-α production and its activity, inhibiting or inhibiting oxidative stress, triglyceride (TG) synthesis, and hepatic stellate cell activation. However, fibroblast growth factor (FGF21) have a variety of adverse effects or contraindications and there is still no consensus regarding the most effective drug therapy for liver steatosis. Therefore, new agents such as active endogenous molecules with high efficacy and minimal side effects are eagerly needed for the treatment of liver steatosis. FGF21 is a hepatic protein that plays a critical role in metabolism, stimulating fatty acid oxidation and liver uptake of fat^[7]. Systemic metabolize of obese rodents adjusted by FGF21 leads to improved glucose homeostasis and weight loss. The concentration of immunity factors reduced and resulted in blood glucose and lipid levels decreased in the fatty rats by administrating FGF21, it proved that FGF21 can improve the metabolic disorders [8,9]. FGF21 changes the degree of inflammation of the liver caused by high fat, indirectly affecting the immune level changes. FGF21 plays an important role in anti-inflammatory responses induced by HFDs in mice. However, the underlying antiinflammatory mechanism remains to be elucidated. In this study, we injected recombinant FGF21 into mice to evaluate the effect of exogenous FGF21 on the immunocytokines in mice fed a HFDs to determine the effect on inflammation.

MATERIAL and METHODS

Ethics

The animal study was approved by the Institutional Animal Care and Use Committee (IACUC). All mice experimental procedures were performed in accordance with the regulations for the Administration of Affairs Concerning Experimental Animals approved by the school Council of Heilongjiang Bayi Agricultural University of China daqing.

Animals

Twenty-four female 4 weeks old KM mice (15-20 g) were purchased from Yongguan Animal Experiment Center, Heilongjiang, China. Twelve mice were fed a HFDs (feed formula: 10% load, 2% bilineurine, 5% albumen powder, 0.3% pig bile salt, and 82.7% basal feed), and the other twelve mice were fed a normal diet; mice were provided free access to the diet food and drinking water. After 30 days, the animals were divided into four groups: 1. HFDs mice below refer to 'model group' (n=6, intraperitoneal injection of 0.9% saline); 2. normal diet mice below refer to 'control group' (n=6, intraperitoneal injection of 0.9%) saline); 3. HFDs mice exogenous injection FGF21 with 200 mg/kg/day FGF21 below refer to 'model + FGF21 group' (n=6, intraperitoneal injection); and 4. normal diet exogenous injection with 200 mg/kg/day FGF21 below refer to 'control + FGF21 group' (n=6, intraperitoneal injection). Mice were sacrificed at 3 and 6 days after injection. The experiment mice were lightly anesthetized and blood was collected from the retro-orbital plexus. The whole blood sample was then centrifuged at 2500 g for 10 min to yield the serum fraction and frozen at -20°C until it was needed for subsequent biochemical analyses. Blood was collected at 3 and 6 days, and after blood collection, the mice were sacrificed, and the liver was removed and fixed in buffered formalin for 24 h and embedded in paraffin wax for histological analyses.

Histological Analyses

The liver tissues were fixed in 10% neutral buffered formaldehyde, embedded in paraffin, and sectioned (4 μ m). The sections were stained with hematoxylin and eosin and observed under a microscope (Nikon, Tokyo, Japan).

Flow Cytometry

Whole blood was collected in anticoagulant tubes and the separation of lymphocytes from peripheral blood lymphocytes was performed (Solarbio, Beijing, China). Monoclonal antibodies against CD3 (SC-20047FITC, PC3/188A, Santa Cruz Biotechnology Inc) and CD19 (SC-8499PE, R20, Santa Cruz Biotechnology Inc) were used. The presence of immune T and B leukomonocytes in serum was analyzed by flow cytometry. For each analysis, 10.000 events were recorded ^[10].

ELISA Assay

Serum IL-4 and IL-6 levels were measured using a commercial ELISA kit (BOSTER, Wuhan, China) according to the manufacturer's guidelines. The optical density was determined at 450 nm using a microplate reader (Thermo Fisher Scientific, Waltham, MA, USA). The calibration curves

63

were constructed by plotting the net average absorbance of the standards on the Y-axis and the concentrations on the X-axis using the logit-log function to linearize and draw the best fitting curve.

Biochemical Index Examination

Serum total cholesterol TC, TG, and NEFA were measured by personnel at the University Hospital of Jilin according to routine clinical chemistry methods (Siemens, Erlangen, Germany).

Statistical Analysis

Data were pooled as mean values ± standard errors. The ANOVA corrected using the Bonferroni test was used to determine differences between groups comparing the internal variability of groups with the variability among all experimental groups. P<0.05 was considered statistically significant. Data were randomly collected and the analyses were performed using IBM SPSS Statistics 22.0 software (SPSS, Chicago, IL, USA).

RESULTS

To study the potential anti-obesity effect of exogenous recombinant FGF21, a HFDs model was successfully established. We first injected the FGF21 protein to HFDs


mice after 30 days days via intraperitoneal injection. The daily doses were 200 mg/kg of FGF21.

Histological Analysis of Liver

Weight gain in HFDs feeding results from the accumulation of adipose tissue. Therefore we performed histological analyses of the liver. The livers of mice were collected after 6 days and analyzed. The number of vacuoles was lower in the model + FGF21 group than in the model group, and vacuole size decreased slightly (Fig. 1c). The normal liver structure of the control group showed normal-sized liver cells, and the liver cord, nuclear circle, and cytoplasm were normal, neatly arranged and located in the central cells (Fig. 1b). The degree of steatosis in the control + FGF21 group has no significant difference compared with the control group. These findings indicated that HFDs feeding resulted in significant hepatic steatosis and liver injury in mice. Based on the results of the NAFLD (nonalcoholic fatty liver disease) diagnostic gold standard, namely the histological analysis, these findings indicated that exogenous injection FGF21 had a significant hepatoprotective effect on HFDsinduced steatosis.


Changes of Cytokines and Biochemical Indices

Next, we investigated how FGF21 suppresses hepatic inflammation. FGF21 affected slightly increased cytokine-



morphology are observed. After consuming a HDFs for 30 days, exogenous injection FGF21 HDFs mice (b) had reduce vacuolar changes compared with obese mice (a)





induced (i.e. TNF- α) inflammatory factor expression (*Fig. 2C*). The changes of IL-4, IL-6, and TNF- α in each group are shown in *Fig. 2*. IL-6, IL-4, and TNF- α levels were significantly higher in the model group than in the model + FGF21 group at 3 and 6 days (P<0.01) (*Fig. 2A,B*). There were no significant difference in IL-4, IL-6, TNF- α between the control group and the exogenous injection group.

TG levels were measured as the main NAFLD markers biochemical indicator. On days 3 and 6, TG was significantly lower in the model exogenous injection group, and on day 3, the model group and the control group were very significantly different (P<0.01). On days 3 and 6, LDL-c,

TC, and NEFA had significantly different between model group and model exogenous injection FGF21 group. HDL-c was followed exogenous injection change. The above results indicate that FGF21 can significantly improve Lipid metabolism in KM HDFs mice.

After 3 days of exogenous injection, blood samples were collected for assessment of serum TC, TG, NEFA, LDL-C, and HDL-C levels using an automatic biochemical analyzer (*Table 1*).

After 6 days of exogenous injection, blood samples were collected for assessment of serum TC, TG, NEFA, LDL-C and

DONG, CHEN, YANG, LI, GAO, HE HUANG, LIU, GUO, CHANG, XIA, XU

Group	TG/mmol·L⁻¹ (mean±SEM)	TC/mmol·L⁻¹ (mean±SEM)	NEFA/mmol·L ⁻¹ (mean±SEM)	LDL-c/mmol·L ^{−1} (mean±SEM)	HDL-c/mmol·L ^{−1} (mean±SEM)
Model (n=3)	0.720±0.072	2.00±0.057	0.440±0.023	0.407±0.012	0.593±0.024
Control (n=3)	0.413±0.073**	1.20±0.050**	0.260±0.031**	0.237±0.027**	0.447±0.053
Model + FGF21 group (n=3)	0.567±0.024	1.67±0.037*	0.340±0.012*	0.297±0.019*	0.807±0.066*
Control + FGF21 group (n=3)	0.537±0.038*	1.23±0.043**	0.233±0.037**	0.287±0.024*	0.693±0.103

Table 2. Effect of FGF21 on the changes in serum lipid parameters at the sixth day							
Group	TG/mmol·L⁻¹ (mean±SEM)	TC/mmol·L⁻¹ (mean±SEM)	NEFA/mmol·L ⁻¹ (mean±SEM)	LDL-c/mmol·L ⁻¹ (mean±SEM)	HDL-c/mmol·L⁻¹ (mean±SEM)		
Model (n=3)	0.673±0.077	1.99±0.068	0.426±0.017	0.400±0.023	0.587±0.035		
Control (n=3)	0.521±0.029**	1.06±0.094**	0.220±0.020**	0.247±0.029**	0.467±0.038		
Model + FGF21 group (n=3)	0.454±0.024*	1.57±0.037**	0.353±0.017*	0.300±0.002**	0.793±0.096*		
Control + FGF21 group (n=3)	0.423±0.052**	1.26±0.219**	0.243±0.015**	0.220±0.058**	0.774±0.070*		
* P<0.05, ** P<0.01 vs. the model group							

HDL-C levels using an automatic biochemical analyzer (*Table 2*).

Different Exogenous Injection FGF21 Days Contast

Compared with the index of model + FGF21 and control + FGF21 on the third day, the index on the sixth day has no significant differences in IL-4, IL-6, TNF- α , TC, NEFA, LDL-c and HDL-c (*Fig. 3*). But the trend of model exogenous injection group to the normal development in IL-4, IL-6, TNF- α , TC, NEFA, LDL-c and HDL-c.

In the model exogenous injection groups, the third day was compared TG, TC, NEFA, LDL-c and HDL-c with the sixth day (*Table 3*).

In the control exogenous injection groups, the third day was compared was compared TG, TC, NEFA, LDL-c and HDL-c with the sixth day (*Table 4*).

Immune Cells

Immune cells from blood of 30-days HDFs mice for 6 days were analyzed by flow cytometry. T lymphocytes (CD3 cells) and B lymphocytes (CD19 cells) showed no marked differences between fat exogenous injection and HDFs mice, and no differences were observed between the control and exogenous injection groups (*Fig. 4*). In the HDFs mice, T (CD3) and B (CD19) lymphocyte numbers showed a similar profile in response to the nutritional challenge, i.e. HDFs does not cause a strong inflammatory response. However, CD3/CD19 values decreased significantly.

DISCUSSION


HFDs can cause chronic inflammation and potentially damage the liver's innate immune system in long - term

edible. The liver is an important organ that plays a critical role in the innate immune system ^[11,12]. The inflammatory response is a complex reaction of the immune system. Activation of lymphocytes plays a pivotal role in the development and progression of inflammation. T and B lymphocytes play a major role in cellular and humoral immunity, in which CD3 cells represent the total number of T lymphocytes and CD19 is an important marker of B lymphocytes.

In our study, we found that FGF21 could improve lymphocytes to reduce inflammation. we investigated the effect of FGF21 on HFDs mice CD3 and CD19. The results showed that blood CD19 was increased in mice fed a HFDs. As the severity of NAFLD increased, CD19 tended to increase, indicating that humoral immune enhancement, which may be involved in the pathogenesis of NAFLD, may be caused by the production of excessive immunoglobulin. The increased percentage of CD3/CD19 cells may be the result of a decrease in the absolute number of other lymphocyte subsets.

In this study, we investigated the mechanism underlying the effect of FGF21 on inflammatory factors in mice fed a HFDs. The results showed that FGF21 effectively reduced TC and NEFA levels and alleviated hepatic damage. The lack of IL-6 expression was associated with exacerbated steatosis in HFD conditions. In our study,The level of serum IL-6 was higher in the model group than that in the control group. An important source of IL-6 in obesity is the expanding visceral adipose tissue mass. Regarding the hepatic lipid metabolism, there is evidence that IL-6 affects the opposing fatty acid pathways: degradation and Synthesis. The HFD-derived effects were aggravated in IL-6deficient mice: higher cholesterol levels and decreased TG levels in serum. In the context of HFD-induced obesity, the


Table 3. Exogenous FGF21 between model groups in serum lipid parameters at the third day and sixth day						
Group	TG/mmol∙L ^{−1} (mean±SEM)	TC/mmol·L⁻¹ (mean±SEM)	NEFA/mmol·L ⁻¹ (mean±SEM)	LDL-c/mmol·L ⁻¹ (mean±SEM)	HDL-c/mmol·L ⁻¹ (mean±SEM)	
Model + FGF21 group at third day (n=3)	0.567±0.024	1.67±0.037	0.340±0.012	0.297±0.019	0.807±0.066	
Model + FGF21 group at sixth day (n=3)	0.454±0.024	1.57±0.037	0.353±0.017	0.300±0.002	0.793±0.096	
* P<0.05, ** P<0.01 vs. the model+FGF21 group						



administration of rlL-6 might contribute to the aggravation of fatty liver disease through increasing lipogenesis ^[13]. IL-6 is considered as an anti-inflammatory cytokine through its inhibitory effects on TNF- α ^[14,15]. FGF21 can effectively change the production of IL-6, thereby reducing the production of TNF- α . In previous studies, the functions of IL-4 were primarily investigated in the immune system, where it exerts pleiotropic effects ranging from Th2 differentiation of helper T cells, activation of B cells to release IgE, and stimulation of alternative macrophage activation ^[16,17]. IL-4 is usually higher in the early stages of inflammation. Because we established a HDFs model, IL-4 values may be high in the model group, however, the exogenous injection in the same period and the relative reduction in IL-4 may indicate a therapeutic effect. Elevated IL-4 levels in

DONG, CHEN, YANG, LI, GAO, HE HUANG, LIU, GUO, CHANG, XIA, XU

Table 4. Exogenous FGF21 between comtrol groups in serum lipid parameters at the third day and sixth day						
Group	TG/mmol∙L ⁻¹ (mean±SEM)	TC/mmol·L⁻¹ (mean±SEM)	NEFA/mmol·L ⁻¹ (mean±SEM)	LDL-c/mmol·L ⁻¹ (mean±SEM)	HDL-c/mmol·L ⁻¹ (mean±SEM)	
Control + FGF21 group at third day (n=3)	0.537±0.038	1.23±0.043	0.233±0.037	0.287±0.024	0.693±0.103	
Control + FGF21 group at sixth day (n=3)	0.423±0.052	1.26±0.219	0.243±0.015	0.220±0.058	0.774±0.070	
* P<0.05, ** P<0.01 vs. the model + FGF21 group						



the control + FGF21 group compared with that in the control group may be due to exogenous injection.

Our result indicated that the model + FGF21 group improved after exogenous injection on days 3 and 6. However, there were no significant differences between days 3 and 6 in the exogenous injection group, which may be due to the fact that the injection cycle was too short. The effects of FGF21 on decreasing body fat in model mice may have been mediated by FGF21-induced suppression of hepatic carbohydrate oxidation may occur via PDK4mediated suppression of PDC activity ^[18]. A HFDs induced hepatic steatosis in mice, leading to increased TG and NEFA. This resulted in NAFLD leading to inflammatory changes in the liver. IL-4, IL-6, and TNF- α were increased by different degrees. FGF21 effectively relieved hepatic fat deformation, inhibited the synthesis of NEFA and TG and reduced the inflammation caused by changes in the inflammatory factors IL-4, IL-6, and TNF- α , and thus alleviated inflammation. Induced by HFDs.

COMPETING INTERESTS

The authors declare that they have no competing interests.

ACKNOWLEDGEMENTS

This research was supported by National Nature Science Foundation of China (31372625), National Nature Science Foundation of China (31672622), and National Program on Key Research Project of China (2016YFD0501206).

REFERENCES

1. Saiki R, Okazaki M, Iwai S: Effects of pioglitazone on increases in visceral fat accumulation and oxidative stress in spontaneously hypertensive hyperlipidemic rats fed a high-fat diet and sucrose solution. *J Pharmacol Sci*, 105 (2): 157-167, 2007. DOI: 10.1254/jphs.FP0070619

2. Lama A, Pirozzi C, Mollica MP: Polyphenol-rich virgin olive oil reduces insulin resistance and liver inflammation and improves mitochondrial dysfunction in high-fat diet fed rats. *Mol Nutr Food Res*, 61 (3): 2017. DOI: 10.1002/mnfr.201600418

3. Esposito E, lacono A G, Autore G: Probiotics reduce the inflammatory response induced by a high-fat diet in the liver of young rats. *Brit J Nutr*, 139 (5): 905-911, 2009. DOI: 10.3945/jn.108.101808

4. Shen M, Shi H: Sex hormones and their receptors regulate liver energy homeostasis. *Int J Endocrinol*, 2015 (2015): Article ID: 294278, 2015. DOI: 10.1155/2015/294278

5. Sozio M S, Liangpunsakul S, Crabb D: The role of lipid metabolism in the pathogenesis of alcoholic and nonalcoholic hepatic steatosis. *Semin Liver Dis*, 30 (4): 378-390, 2010. DOI: 10.1055/s-0030-1267538

6. Deng Z B, Liu Y, Liu C: Immature myeloid cells induced by a high-fat diet contribute to liver inflammation. *Hepatology*, 50 (5): 1412-1420, 2009. DOI: 10.1002/hep.23148

7. Xu C, Xu Q, Chen Y: The relationship between fibroblast growth factor-21 and characteristic parameters related to energy balance in dairy cows. *BMC Vet Res*, 11 (1): 1-7, 2015. DOI: 10.1186/s12917-015-0585-4

8. Jing X, Lloyd D J, Clarence H: Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. *Diabetes*, 58 (1): 250-259, 2009. DOI: 10.2337/db08-0392

9. Kharitonenkov A, Shiyanova TL, Koester A: FGF-21 as a novel metabolic regulator. *J Clin Invest*, 115, 1627-1635, 2015. DOI: 10.1172/JCI23606

10. Liu W, Yin Y, Zhou Z, He M, Dai Y: OxLDL-induced IL-1beta secretion promoting foam cells formation was mainly via CD36 mediated ROS production leading to NLRP3 inflammasome activation. *Inflamm Res*, 63, 33-43, 2013. DOI: 10.1007/s00011-013-0667-3

11. Gao B, Jeong W I, Tian Z: Liver: An organ with predominant innate immunity. *Hepatology*, 47 (2): 729, 2008. DOI: 10.1002/hep.22034

12. Zheng SG: The critical role of TGF-β1 in the development of induced Foxp3+ regulatory T cells. *Int J Clin Exp Med*, 1 (3): 192-202, 2008.

13. Vida M, Gavito AL, Pavón FJ: Chronic administration of recombinant IL-6 upregulates lipogenic enzyme expression and aggravates high-fatdiet-induced steatosis in IL-6-deficient mice. *Dis Mod Mech*, 8 (7): 721-731, 2015. DOI: 10.1242/dmm.019166

14. Aderka D, Le JM, Vilcek J: IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice. *J Immunol*, 143 (11): 3517-3523, 1989.

15. Di Santo E, Alonzi T: Differential effects of IL-6 on systemic and central production of TNF: A study with IL-6-deficient mice. *Cytokine*, 9 (5): 300, 1997. DOI: 10.1006/cyto.1996.0169

16. Shuai K, Liu B: Regulation of JAK-STAT signalling in the immune system. *Nat Rev Immunol*, 3 (11): 900-911, 2003. DOI: 10.1038/nri1226

17. Takeda K, Kishimoto T, Akira S: STAT6: Its role in interleukin 4-mediated biological functions. *J Mol Med-JMM*, 75 (5): 317-326, 1997. DOI: 10.1007/s001090050117

18. Samms RJ, Murphy M, Fowler MJ: Dual effects of fibroblast growth factor 21 on hepatic energy metabolism. *J Endocrinol*, 227 (1): 37-47, 2015. DOI: 10.1530/JOE-15-0334